ADC targeting both PSMA and STEAP1 with a topoisomerase payload showed a 15-month PFS signal in heavily pretreated prostate cancer—far above historical chemotherapy benchmarks.
Tanya Barauskas Dorff, MD, FASCO
Advertisement
Articles by Tanya Barauskas Dorff, MD, FASCO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies
3
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
4
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
5